NCT03907475 2026-04-13
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
4 trialsNCT07423078 2026-04-13
WOLF
University of Pittsburgh
Phase 2 Recruiting
NCT05431270 2025-01-31
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
Phase 1/2 Recruiting
NCT05631886 2023-08-28
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Chinese PLA General Hospital
Phase 1 Recruiting